ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody

Ye, Jing; Jia, Yujie; Tuhin, Israth Jahan; Tan, Jingwen; Monty, Masuma Akter; Xu, Nan; Kang, Liqing; Li, Minghao; Lou, Xiaoyan; Zhou, Meixia; Fang, Xiaoyan; Shao, Jiaqi; Zhu, Hongjia; Yan, Zhiqiang*; Yu, Lei*new
Molecular Therapy-Oncolytics2022-3-17DOI: 10.1016/j.omto.2022.02.013
10被引4阅读
引用收藏
分享

摘要

Although chimeric antigen receptor (CAR) T cell immunotherapy has shown promising significance in B cell malignancies, success against T cell malignancies remains unsatisfactory because of shared antigenicity between normal and malignant T cells, resulting in fratricide and hindering CAR production for clinical treatment. Here, we report a new strategy of blocking the CD7 antigen on the T cell surface with a recombinant anti-CD7 antibody to obtain a sufficient amount of CD7-targeting CAR-T cells for T cell acute lymphoblastic leukemia (T-ALL) treatment. Feasibility was evaluated systematically, revealing that blocking the CD7 antigen with an antibody effectively blocked CD7-derived fratricide, increased the expansion rate, reduced the proportion of regulatory T (Treg) cells, maintained the stem cell-like characteristics of T cells, and restored the proportion of the CD8(+) T cell population. Ultimately, we obtained anti-CD7 CAR-T cells that were specifically and effectively able to kill CD7 antigen-positive target cells, obviating the need for complex T cell modifications. This approach is safer than previous methods and provides a new, simple, and feasible strategy for clinical immunotherapies targeting CD7-positive malignant tumors.

学科与关键词

关键词
CHIMERIC ANTIGEN RECEPTORMEMORY STEM-CELLSB-CELLTISAGENLECLEUCELIMMUNOTHERAPYMECHANISMSEXPRESSIONLEUKEMIATHERAPYCD7
相关
加载中…
  • T-ALL Cells as Tool Cells for CAR T Therapy
    Ren, Anqi; Zhao, Yuan; Zhu, Haichuan*Vaccines, 2023, 11(4): 854.被引 1
  • CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
    Ren, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*Vaccines, 2023, 11(1): 165.被引 7
  • Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Therapy-Oncolytics
发表日期
2022-03-17
卷期
第 24 卷
页码
719-728
DOI
10.1016/j.omto.2022.02.013
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81872812, 82073800]

作者

  • Y

    Ye, Jing (第一作者)

    new

  • J

    Jia, Yujie

查看全部 15 位作者收起作者
  • T

    Tuhin, Israth Jahan

    new

  • T

    Tan, Jingwen

    new

  • M

    Monty, Masuma Akter

  • X

    Xu, Nan

    new

  • K

    Kang, Liqing

  • L

    Li, Minghao

    new

  • L

    Lou, Xiaoyan

  • Z

    Zhou, Meixia

    new

  • F

    Fang, Xiaoyan

    new

  • S

    Shao, Jiaqi

    new

  • Z

    Zhu, Hongjia

    new

  • Y

    Yan, Zhiqiang (通讯)

    new

  • Y

    Yu, Lei (通讯)

    new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417